CA-ARMIS
18.6.2024 15:31:26 CEST | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced Main Line Health is leveraging the Armis Centrix™ platform for full visibility and control over all connected assets within its hospital system as it drives operational innovation to advance patient safety.
With multiple hospitals and facilities, Main Line Health has a vast network of IT, IoT and IoMT assets. Through Armis Centrix™, the hospital system quickly identified 2x more devices than previously estimated – including biomedical devices. Utilizing two solutions from Armis, Armis Centrix™ for Medical Device Security and Armis Centrix™ for Vulnerability Prioritization and Remediation, Main Line Health has been able to build a more cohesive security ecosystem and automate compliance. This has also driven increased awareness within the organization about the importance of cyber resiliency initiatives that boost greater operational efficiency while minimizing clinical disruption.
“Armis is an integral part of Main Line Health’s cybersecurity program, providing unparalleled visibility into every asset and device within our environment,” said Aaron Weismann, Chief Information Security Officer at Main Line Health. “As a hospital system dedicated to delivering safe, high-quality, equitable and affordable care to treat and cure disease, Armis allows us to focus on what truly matters.”
Rapidly evolving care models, combined with the accelerated adoption of technology, have increased the attack surface for healthcare organizations. In the U.S. alone, ransomware attacks in healthcare were up 128% from 2022 to 2023, reinforcing the need for a comprehensive cyber resilience strategy.
“Armis understands the unique cybersecurity challenges within the healthcare industry, including safeguarding valuable data, ensuring continuity of care and preventing disruptive attacks that put patients – and the organization – at risk,” said Mohammad Waqas, CTO, Healthcare at Armis. “We congratulate Main Line Health for its recent award recognition in cybersecurity excellence as it improves patient safety and treatment outcomes by enhancing cyber resilience.”
The AI-powered Armis Centrix™ platform proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface.
Healthcare organizations continue to be heavily targeted by cyberattackers, especially in the last few months, which can lead to extended downtime and compromise patient safety. Armis Centrix™ provides complete visibility and security across all managed and unmanaged medical devices, clinical assets and the entire healthcare ecosystem – with zero disruption to patient care.
For additional details on how Main Line Health is driving innovation with Armis Centrix™, please read the full case study.
Learn more about how Armis helps to secure the health and medical industry here.
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618954357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
Belkin præsenterer nye løsninger til at strømforsyne, lokalisere og personalisere hverdagens teknologi3.9.2026 10:00:00 CEST | Pressemeddelelse
Belkin International kan findes på IFA-messen i udstillingshal 3.2, stand nr. 117 Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag en ny kollektion af tilsluttet tilbehør, enhedsbeskyttelse og livsstilsløsninger, der er designet til at hjælpe forbrugerne med at holde styr på og personalisere de enheder, de er afhængige af. Den nye portefølje omfatter SureFind-kollektionen, BoostCharge Slim Magnetic Ring Stand, UltraCharge Smart Display-powerbanks og nye farvevarianter af Belkins populære BoostCharge Compact USB-C-oplader 30 W. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903932800/da/ Product lineup showcasing Belkin's newest mobile power accessories De nye produkter bygger på idéen om, at teknologi skal passe problemfrit ind i en moderne l
Quectel Expands RG660Qx 5G Module Capabilities for Future Railway Mobile Communication System Evaluation and Railway Applications3.9.2026 10:00:00 CEST | Press release
High-performance Sub-6GHz 5G module platform with support for FRMCS-related frequency bands enables early evaluation through a dedicated development environment. Quectel Wireless Solutions, a global IoT solutions provider, today announced an LGA version of its RG660Qx 5G module series, a high performance, Sub-6GHz 5G module platform that includes support for the Future Railway Mobile Communication System (FRMCS). Used with a dedicated evaluation environment comprising an adaptor board and EVB Kit, the RG660Qx enables equipment manufacturers and railway technology developers to conduct early Future Railway Mobile Communication System (FRMCS) evaluation and testing, supporting development ahead of the transition from GSM-R. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903961434/en/ Quectel expands RG660Qx 5G module capabilities for Future Railway Mobile Communication System evaluation and railway applications The Future R
Belkin introducerer fremtidens bærbare strømforsyning med nye UltraCharge Pro Power Banks med halvfaste celler3.9.2026 10:00:00 CEST | Pressemeddelelse
Den næste generation af bærbar strømforsyning præsenteres for første gang på IFA 2026 og fremviser avanceret BoostSolid Cell-teknologi og ultraslanke design Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag nye bærbare opladningsløsninger baseret på halvfast celleteknologi. Den nye UltraCharge Pro med BoostSolid Cell-serie er blandt Belkins første produkter med halvfast celleteknologi, et batteri af næste generation, der leverer forbedret holdbarhed, slankt design og længere batteritid – alt sammen uden at gå på kompromis med ydeevnen. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903417354/da/ Product image showcasing the first two Belkin power banks launched with BoostSolid technology Batteriteknologi af næste generation til længerevarende
I’m green™ bio-based Helps Deterra® Win Multiple Industry Awards for Pharmaceutical Packaging3.9.2026 10:00:00 CEST | Press release
The Deterra® Drug Disposal Pouch, which is made with 50% or more I'm green™ bio-based polymer, has gained Accredo Packaging a number of leading packing industry awards. Developed by Verde, the patented drug disposal technology is designed to deactivate unused medications, preventing drug diversion and mitigating the risk of pharmaceuticals leaching into groundwater and waterways. The partial use of I’m green™ bio-based polymer derived from renewable sugarcane, reduces the carbon footprint of the packaging material compared to equivalent fossil-based polyethylene, all whilst maintaining the technical performance required for pharmaceutical disposal applications. Material Innovation and Application The Deterra® pouch required a material that could meet strict technical specifications without relying entirely on traditional, fossil-based plastics. By utilizing I’m green™ bio‑based polyethylene, the packaging has a reduced carbon footprint whilst maintaining the performance of conventional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
